Katherine Stueland - May 16, 2023 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Role
Chief Executive Officer, Director
Signature
/s/ Bridget Brown, Attorney-in-Fact
Stock symbol
WGS
Transactions as of
May 16, 2023
Transactions value $
-$56,439
Form type
4
Date filed
5/18/2023, 07:21 PM
Previous filing
May 2, 2023
Next filing
Jun 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WGS Class A Common Stock Sale -$56.4K -8.69K -34.95% $6.50 16.2K May 16, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 represents shares sold by the Reporting Person in a broker-assisted transaction to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $7.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 of this Form 4.

Remarks:

All numbers presented above reflect share amounts after giving effect to the 33:1 reverse stock split the Issuer's stockholders approved on April 14, 2023, which was previously announced in the Current Report on Form 8-K filed by the Issuer on April 17, 2023, and which became effective on May 4, 2023.